Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).

Literature DB >> 8105866

Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).

L Capolongo¹, G Melegaro, M Broggini, N Mongelli, M Grandi.

Abstract

Human colon adenocarcinoma cells (LoVo) resistant to the new antitumor agent FCE 24517 [benzoyl-mustard derivative of distamycin A] (LoVo/24517) are resistant to the selecting agent and related molecules as well as to vinblastine, with marginal or no resistance to other antitumour drugs. Treatment with verapamil, tamoxifen, nicergoline or cyclosporin A only partially restores the activity of FCE 24517 against LoVo/24517 cells. Such results suggest that resistance mechanisms possible specific for this class of compounds are operating.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1993 PMID： 8105866 PMCID： PMC1968750 DOI： 10.1038/bjc.1993.454

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

14 in total

1. In vitro bone marrow purging of multidrug-resistant cells with a mouse monoclonal antibody directed against Mr 170,000 glycoprotein and a saporin-conjugated anti-mouse antibody.

Authors: A Dinota; P L Tazzari; M Michieli; G Visani; M Gobbi; A Bontadini; C Tassi; R Fanin; D Damiani; M Grandi
Journal: Cancer Res Date: 1990-07-15 Impact factor: 12.701

2. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line.

Authors: B Drewinko; M M Romsdahl; L Y Yang; M J Ahearn; J M Trujillo
Journal: Cancer Res Date: 1976-02 Impact factor: 12.701

3. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues.

Authors: A Ramu; D Glaubiger; Z Fuks
Journal: Cancer Res Date: 1984-10 Impact factor: 12.701

4. Isolation and expression of a complementary DNA that confers multidrug resistance.

Authors: P Gros; Y B Ben Neriah; J M Croop; D E Housman
Journal: Nature Date: 1986 Oct 23-29 Impact factor: 49.962

5. The molecular origin of DNA-drug specificity in netropsin and distamycin.

Authors: M L Kopka; C Yoon; D Goodsell; P Pjura; R E Dickerson
Journal: Proc Natl Acad Sci U S A Date: 1985-03 Impact factor: 11.205

6. Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.

Authors: F M Arcamone; F Animati; B Barbieri; E Configliacchi; R D'Alessio; C Geroni; F C Giuliani; E Lazzari; M Menozzi; N Mongelli
Journal: J Med Chem Date: 1989-04 Impact factor: 7.446

7. Reversal of adriamycin resistance by verapamil in human ovarian cancer.

Authors: A M Rogan; T C Hamilton; R C Young; R W Klecker; R F Ozols
Journal: Science Date: 1984-06-01 Impact factor: 47.728

8. Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements.

Authors: M Broggini; M Ponti; S Ottolenghi; M D'Incalci; N Mongelli; R Mantovani
Journal: Nucleic Acids Res Date: 1989-02-11 Impact factor: 16.971

9. Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.

Authors: C Geroni; E Pesenti; G Tagliabue; D Ballinari; N Mongelli; M Broggini; E Erba; M D'Incalci; F Spreafico; M Grandi
Journal: Int J Cancer Date: 1993-01-21 Impact factor: 7.396